Karyopharm Therapeutics Inc. (KPTI) Stock Analysis

Karyopharm Therapeutics (KPTI) is a commercial-stage oncology company built around a differentiated mechanism: inhibiting **XPO1-mediated nuclear export**, which in many cancers is overactive and functionally disables tumor suppressors like p53 by removing them from the nucleus. Its flagship product, **XPOVIO (selinexor)**—the first-in-class oral XPO1 inhibitor—aims to restore tumor suppressor activity and is marketed in the U.S. for relapsed/refractory **multiple myeloma** and **DLBCL**. In FY2025, Karyopharm generated **$146.1M** of total revenue (essentially flat YoY), led by **$114.9M** in U.S. net product sales and **$31.2M** from licenses/milestones/other. Domestically, ~**60%** of product revenue is driven by community oncology settings (40% academic), suggesting real-world adoption beyond specialty centers; internationally, selinexor is approved in 50+ countries and monetized through partnerships (e.g., Menarini in Europe; Antengene in APAC). The investment case is dominated by a looming clinical-and-financing inflection: the company’s value is increasingly tied to pivotal Phase 3 readouts (notably **SENTRY in myelofibrosis in March 2026**) as it attempts to expand beyond a competitive myeloma franchise while managing a distressed balance sheet and limited cash runway.